Verona Pharma Plc ADR [NASDAQ: VRNA] price plunged by -1.78 percent to reach at -$0.49.
The one-year VRNA stock forecast points to a potential upside of 24.48. The average equity rating for VRNA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Verona Pharma Plc ADR [VRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRNA shares is $35.79 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRNA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Verona Pharma Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 22, 2023. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on September 19, 2022, representing the official price target for Verona Pharma Plc ADR stock. Previously, the target price had yet another raise to $31, while Piper Sandler analysts kept a Overweight rating on VRNA stock.
The Average True Range (ATR) for Verona Pharma Plc ADR is set at 1.65 The Price to Book ratio for the last quarter was 13.02, with the Price to Cash per share for the same quarter was set at 4.99.
VRNA Stock Performance Analysis:
Verona Pharma Plc ADR [VRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.45. With this latest performance, VRNA shares gained by 28.96% in over the last four-week period, additionally plugging by 60.70% over the last 6 months – not to mention a rise of 38.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRNA stock in for the last two-week period is set at 60.11, with the RSI for the last a single of trading hit 56.71, and the three-weeks RSI is set at 61.68 for Verona Pharma Plc ADR [VRNA]. The present Moving Average for the last 50 days of trading for this stock 22.54, while it was recorded at 27.05 for the last single week of trading, and 17.55 for the last 200 days.
Insight into Verona Pharma Plc ADR Fundamentals:
Verona Pharma Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.61 and a Current Ratio set at 8.61.
VRNA Stock EPS
With the latest financial reports released by the company, Verona Pharma Plc ADR posted -0.18/share EPS, while the average EPS was predicted by analysts to be reported at -0.28/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.1. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VRNA.
Verona Pharma Plc ADR [VRNA] Institutonal Ownership Details
There are presently around $91.76%, or 95.48%% of VRNA stock, in the hands of institutional investors. The top three institutional holders of VRNA stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7.63 million shares, which is approximately 9.4566%. NEA MANAGEMENT COMPANY, LLC, holding 5.58 million shares of the stock with an approximate value of $$80.76 million in VRNA stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $$57.84 million in VRNA stock with ownership which is approximately 4.9559%.
